Loading
Loading
Research Overview
Dual GLP-1 and glucagon receptor agonist; GLP-1R activity suppresses appetite and prevents glucagon-mediated hyperglycaemia while GCGR activation drives hepatic fatty acid oxidation, thermogenesis, and lipolysis — producing weight loss with particular hepatic lipid reduction.
Pemvidutide combines GLP-1 receptor agonism (for appetite suppression and insulin sensitisation) with glucagon receptor agonism (for hepatic fatty acid oxidation, thermogenesis, and energy expenditure) in a weekly subcutaneous injection. The GLP-1 component manages the hyperglycaemia that glucagon receptor activation would otherwise cause, enabling the thermogenic and lipolytic benefits of glucagon activation.
The compound's clinical differentiation from competing dual agonists is its particularly strong effect on liver fat reduction, making it a focused development candidate for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) alongside its obesity indication. Phase 2 data has demonstrated reductions in liver fat fraction that position pemvidutide in the MASH treatment landscape alongside semaglutide and resmetirom.
Pemvidutide is a direct competitor to retatrutide and survodutide in the GLP-1/glucagon dual agonist space, distinguished by its development track and specific emphasis on hepatic endpoints alongside weight loss metrics.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, pemvidutide has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Pemvidutide research is most relevant to protocols examining:
GLP-1/glucagon dual agonism research with hepatic fat focus
MASLD and NASH liver disease model studies
Body composition research with superior lean mass preservation
Researchers comparing Pemvidutide vs Survodutide vs Retatrutide
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Measurable effects begin to establish. Mid-cycle assessment is appropriate at this point in well-designed protocols.
Peak activity window
Primary outcomes are typically strongest in this window. Human trial literature provides benchmarks for comparison.
Washout & review
Allow full washout (~5× half-life: ~5 days). Review data, confirm baseline recovery before any repeat protocol.
Dual GLP-1 and glucagon receptor agonist; GLP-1R activity suppresses appetite and prevents glucagon-mediated hyperglycaemia while GCGR activation drives hepatic fatty acid oxidation, thermogenesis, and lipolysis — producing weight loss with particular hepatic lipid reduction.
| Parameter | Value |
|---|---|
| Dose range | 1.2–2.4 mg/week (trial range) |
| Schedule | Once weekly |
| Route | Subcutaneous |
| Half-life | ~5 days |
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.